Synthesis, characterization, and heparin-binding study of a self-assembled p-cymene-Ru(ii) metallocycle based on a 4-amino-1,8-naphthalimide Tröger's base supramolecular scaffold

Abstract

We report the very first example of a self-assembled p-cymene-Ru(II) metallocycle based on a green emitting 4-amino-1,8-naphthalimide Tröger’s base (TBNap) supramolecular scaffold. A new cleft-shaped TBNap-derived di-4-picolyl donor was synthesized...

Recent advances in fluorescence-based chemosensing of organoarsenic feed additives using luminescence MOFs, COFs, HOFs, and QDs

“…50 The static or dynamic quenching mechanisms give a linear Stern–Volmer curve and the Stern–Volmer quenching constant ( K SV ) can be determined from the slope of the linear curve. 51 The higher value of K SV indicates that sensor molecules strongly bind with the target analytes resulting in strong fluorescence quenching. 52,53 The following sections describe the structures, photophysics, and fluorescence sensing mechanisms of different kinds of fluorescence sensors for organoarsenic feed additives sensing.…”

Tracking the cellular uptake and phototoxicity of Ru(ii)-polypyridyl-1,8-naphthalimide Tröger's base conjugates

“…[3][4][5][6][7][8][9][10][11][12][13] Likewise, Shanmugaraju and co-workers have recently developed several excellent examples of naphthalimide Tro ¨ger's bases and demonstrated their application in a range of supramolecular chemistry applications. [14][15][16][17][18] Ru(II) polypyridyl complexes are known DNA and RNA targeting agents, but a School of Biochemistry and Immunology, Biomedical Sciences Institute, Trinity biological profiling of such complexes has only recently been appreciated and studied in some detail. [19][20][21][22][23][24][25][26][27][28] Hence, the pursuit of Ru(II) polypyridyl complexes as cellular imaging agents and potential theranostics is gathering pace with the recent progression of the thiophane containing TLD1433 to a phase II study for treating non-muscle invasive bladder cancer -the first ruthenium polypridyl based PDT agent to progress to clinical trials.…”